FDA Approves Gedatolisib, Bringing the First Pan-PI3K/mTOR Targeted Therapy to Patients with Advanced Breast Cancer
发布时间:
2026-07-21 00:00
Recently, the U.S. Food and Drug Administration (FDA) approved Gedatolisib, a pan-PI3K/mTOR inhibitor developed by Celcuity, for use in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), locally advanced or metastatic breast cancer who have disease progression following at least one prior line of endocrine therapy in the metastatic setting and whose tumors do not harbor PIK3CA mutations. This approval makes Gedatolisib the first FDA-approved therapy capable of simultaneously inhibiting all Class I PI3K isoforms (α, β, δ, and γ) as well as mTORC1 and mTORC2, providing a new targeted treatment option for patients with PIK3CA wild-type HR+/HER2− advanced breast cancer.
HR+/HER2− breast cancer represents the most common molecular subtype of breast cancer, accounting for approximately 70% of all breast cancer cases, among which approximately 60% of patients harbor wild-type PIK3CA. For these patients, treatment options after disease progression following endocrine therapy combined with CDK4/6 inhibitors have historically been limited. Gedatolisib achieves comprehensive blockade of the PI3K/AKT/mTOR (PAM) signaling pathway by simultaneously inhibiting all Class I PI3K isoforms and mTORC1/2, potentially reducing compensatory pathway activation associated with single-target inhibition and overcoming endocrine therapy resistance through a mechanistic approach.
The approval was primarily supported by data from the PIK3CA wild-type cohort of the global Phase 3 VIKTORIA-1 clinical trial. In May 2026, Celcuity announced positive topline results from the study. The results demonstrated that the triple combination regimen of Gedatolisib plus palbociclib and fulvestrant met the primary endpoint, achieving a median progression-free survival (PFS) of 9.3 months compared with 2.0 months in the control group, representing a 76% reduction in the risk of disease progression or death. The dual combination regimen of Gedatolisib plus fulvestrant also demonstrated significant efficacy, with a median PFS of 7.4 months, substantially exceeding that of the control arm. In addition, both regimens significantly improved objective response rates and demonstrated durable responses, further validating the clinical potential of Gedatolisib in PIK3CA wild-type patients and providing critical support for its FDA approval.
Alongside the release of the Phase 3 results, Celcuity announced plans to submit a supplemental New Drug Application (sNDA) to the FDA in the third quarter of 2026 to expand the indication of Gedatolisib to patients with PIK3CA-mutated HR+/HER2− locally advanced or metastatic breast cancer. The application will be based on data from the PIK3CA-mutated cohort of the VIKTORIA-1 study, with relevant findings presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. If successful, this expansion could further broaden the eligible patient population for Gedatolisib.
Notably, Gedatolisib is not an entirely new drug candidate. The compound was originally developed by Pfizer; however, its development was temporarily discontinued due to challenges including tolerability issues encountered during early-stage development. In 2021, Celcuity obtained global development and commercialization rights to Gedatolisib from Pfizer through a transaction involving a $10 million upfront payment plus potential milestone payments. The company subsequently optimized the clinical development strategy by evaluating Gedatolisib in combination with endocrine therapy and CDK4/6 inhibitors, with a particular focus on patients with PIK3CA wild-type tumors. With the successful outcome of the VIKTORIA-1 trial and FDA approval, this previously discontinued development program has undergone a transformation from early setbacks to successful commercialization, serving as a representative example of drug redevelopment and optimization of combination treatment strategies.
The journey of Gedatolisib, from a once-discontinued drug candidate to an FDA-approved therapy, highlights the long-term and complex nature of innovative drug development. Beyond its clinical achievements, the intellectual property landscape surrounding Gedatolisib is also noteworthy. According to the WisdomAI database, Gedatolisib-related compound patents have entered nearly 60 countries and regions through pathways such as the Patent Cooperation Treaty (PCT), with 101 patent application families filed globally. More than 80% of these applications have been granted and remain in force, indicating broad recognition of the compound’s patentability across multiple patent offices and relatively strong patent stability.
In China, Gedatolisib is protected by two granted compound patents, with grant publication numbers CN102036995B (parent application) and CN104230831B (divisional application). Both patents are estimated to expire on May 21, 2029. Currently, the patent owners of these two Chinese patents remain Wyeth LLC, a subsidiary of Pfizer, and no assignment or transfer of patent ownership has been recorded. Therefore, it is reasonable to speculate that Pfizer and Celcuity may have entered into an exclusive license agreement covering these patent rights.
立即咨询
如果您对我们的产品感兴趣,请留下您的电子邮件,我们将尽快与您联系,谢谢!